Selexipag denied for failing step therapy by Humana?

Humana's specific coverage criteria for selexipag are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Applies Step Therapy to Selexipag

Humana's step-therapy (also called "fail-first") requirement for selexipag reflects the insurer's position that certain less expensive PAH agents should be trialed before a prostacyclin receptor agonist is approved. A step-therapy denial typically means the prior authorization review found that documentation of required prior agent trials was absent, incomplete, or that the stated outcomes of prior therapy were not considered sufficient to waive the step requirement.

## Why This Denial Is Appealable

Many states have enacted step-therapy reform laws that limit how insurers can apply fail-first requirements — particularly when a prescriber documents that the required prior steps are clinically contraindicated, have already been tried, or that requiring them would cause harm. Even in states without such laws, federal external review rights apply when a step-therapy denial results in an adverse benefit determination.

## Your Federal Appeal Rights

• Step-therapy exception / internal appeal: Most plans have an explicit exception process. Your prescriber must document that: (a) the required step drugs were already tried with inadequate response or intolerance, or (b) the step drugs are contraindicated or otherwise clinically inappropriate for this patient.
• ACA §2719 / External Review: After an adverse internal decision, independent external review is available — generally within approximately four months of the denial. External reviewers apply medical evidence standards, not just the insurer's step protocol.
• ERISA §503 (employer plans): Entitles you to a full-and-fair review and the complete clinical criteria used to design the step requirement.
• State law: If you are on a fully-insured plan regulated by your state's insurance department, check whether your state has a step-therapy override law that provides additional protections.
• Expedited review: Available if delay would seriously jeopardize your health.

## Appeal Timeline

1. Identify precisely which step agents Humana requires and obtain that criteria in writing. 2. Compile prior-therapy documentation for every required step — include dates, duration, documented response, and reason for discontinuation. 3. File the exception or internal appeal, directly addressing every step criterion. 4. Escalate to external review if the internal appeal is upheld.

## Documentation to Gather

• Prior therapy records: Chart notes, pharmacy records, and prescriber notes documenting every PAH agent trialed, with dates, treatment duration, and clinical outcomes or adverse effects.
• Step-waiver justification: A prescriber letter explaining why each required step drug was not or cannot be used — citing specific clinical findings, intolerance, or contraindication per the patient's chart.
• Current clinical status: Functional class assessment, recent labs, and hemodynamic data showing current disease burden and need for advancement of therapy.
• Diagnosis confirmation: Confirming PAH and any comorbidities relevant to step-drug appropriateness.
• Applicable guideline reference: A general reference to the relevant guideline organization's treatment algorithm, without citing specific numbers, to contextualize the prescriber's reasoning.

## Criteria-Mapping Structure

Obtain Humana's step-therapy protocol for selexipag. List each required prior step in a table. For each step, document in the adjacent column either the trial dates and outcome, or the specific clinical reason the step is not appropriate for this patient. This structure forces the reviewer to address each element individually rather than issuing a blanket denial.